genu
flaviviru
belong
flavivirida
famili
includ
singlestrand
plussens
rna
viral
speci
flavivirus
human
medic
import
tick
mosquitotransmit
virus
typic
repres
tickborn
enceph
viru
tbev
omsk
hemorrhag
fever
viru
ohfv
kyasanur
forest
diseas
viru
kfdv
alkhurma
hemorrhag
fever
viru
ahfv
powassan
viru
powv
west
nile
viru
wnv
dengu
viru
denv
japanes
enceph
viru
jev
yellow
fever
viru
yfv
zika
viru
zikv
flavivirida
famili
also
includ
less
known
neglect
virus
loup
ill
viru
liv
usutu
viru
langat
viru
wesselsbron
flavivir
genom
singlestrand
plussens
rna
kb
length
encod
singl
polyprotein
co
posttransl
process
three
structur
capsid
premembran
membran
envelop
seven
nonstructur
protein
protein
possess
enzymat
activ
report
import
target
antivir
develop
wherea
act
serin
proteas
triphosphatas
nucleosid
triphosphatas
ntpase
consist
complex
contain
rnadepend
rna
polymeras
rdrp
methyltransferas
mtase
flavivir
infect
accompani
wide
spectrum
distinct
clinic
manifest
rang
rel
mild
fever
arthralgia
sever
viscerotrop
symptom
yfv
denv
hemorrhag
fever
kfdv
ohfv
encephalitismyel
jev
wnv
tbev
neuropath
teratogen
manifest
zikv
million
clinic
case
flavivir
infect
includ
numer
death
report
annual
current
specif
antivir
therapi
avail
treat
patient
flavivir
infect
thu
search
safe
effect
smallmolecul
inhibitor
would
activ
virus
repres
high
research
nucleosid
analog
inhibitor
figur
promin
search
effect
antivir
nucleosid
analog
synthet
chemic
modifi
nucleosid
mimic
physiolog
counterpart
endogen
nucleosid
block
cellular
divis
viral
replic
impair
dnarna
synthesi
inhibit
cellular
viral
enzym
involv
nucleosidetid
metabol
figur
first
antivir
analog
develop
late
current
approv
therapeut
nucleosid
use
therapi
viral
infect
high
medic
import
hivaid
tenofovir
hepat
b
lamivudineentecavir
hepat
c
sofosbuvir
herp
infect
acyclovir
far
numer
nucleosid
analog
describ
inhibit
arthropodtransmit
flavivirus
sinc
virus
close
relat
hepat
c
viru
hcv
mani
potent
inhibitor
current
develop
antihcv
nucleosid
analog
repres
promis
tool
repurpos
virus
within
flavivirida
aim
review
provid
overview
known
antivir
agent
target
select
arthropodborn
flavivirus
discuss
characterist
properti
mode
action
advantag
limit
therapeut
use
moreov
import
challeng
complic
antiflaviviru
nucleosid
analog
develop
highlight
possibl
strategi
overcom
shortcom
suggest
nucleosid
analog
activ
arthropodborn
flavivirus
usual
classifi
accord
target
viral
life
cycl
antivir
molecul
act
inhibitor
flavivir
nucleosid
scaffold
suppress
host
cell
enzym
involv
particularli
nucleosid
biosynthet
case
exhibit
multipl
mode
vitro
antivir
effect
cytotox
profil
import
antiflaviviru
nucleosid
analog
summar
tabl
overview
vivo
antiflavivir
activ
select
nucleosid
evalu
differ
anim
model
present
tabl
substitut
cnucleosid
deriv
develop
gilead
scienc
inc
treatment
filoviru
infect
also
show
reason
antivir
activ
paramyxo
within
flavivirida
famili
compound
exert
micromolar
inhibitori
activ
yfv
valu
respect
variou
cellbas
screen
surprisingli
consider
less
favor
vitro
activ
report
wnv
tickborn
flavivirus
ahfv
kfdv
tbev
phosphoramid
prodrug
refer
recent
enter
phase
ii
clinic
trial
treatment
ebola
infect
display
higher
antivir
effect
member
tbev
serocomplex
compar
parent
analog
increas
antivir
potenc
could
relat
improv
convers
prodrug
biolog
activ
form
howev
report
si
valu
indic
low
therapeut
potenti
nucleosid
treat
flavivir
substitut
molecul
posit
methyl
vinyl
moieti
yield
compound
consider
reduc
potenc
narrow
spectrum
antivir
scaffold
repres
initi
major
class
therapeut
nucleosid
develop
merck
research
laboratori
demonstr
potent
inhibit
hcv
antivir
activ
nucleosid
beyond
flavivirida
famili
report
repres
picornavirida
calicivirida
indic
potenti
broadspectrum
inhibitori
activ
compound
within
posit
singlestrand
rna
virus
substitu
introduc
nucleosid
appear
import
structur
element
highli
select
micromolar
inhibit
tickborn
flavivirus
particularli
tbev
ahfv
kdfv
ohfv
powv
assay
porcin
stabl
kidney
cell
ps
human
neuroblastoma
cell
adenocarcinom
human
alveolar
basal
epitheli
cell
mosquitotransmit
flavivirus
nucleosid
inhibit
wnv
denv
yfv
cellbas
cellfre
report
assay
system
show
low
micromolar
antivir
phosphoramid
prodrug
denot
exert
nanomolar
inhibitori
activ
combin
ribavirin
result
signific
synergist
antidenv
activ
togeth
speci
first
describ
nucleosidebas
inhibitor
zikv
epidemiolog
outbreak
oceania
latin
show
antizikv
potenc
immort
cell
line
also
induc
pluripot
stem
cellderiv
neuron
cell
type
cortic
neuron
motor
neuron
triphosph
analog
nucleosid
exhibit
strong
inhibitori
activ
polymerasebas
vitro
assay
use
activ
recombin
zikv
strong
antiflavivir
activ
sever
modifi
nucleosid
also
demonstr
use
numer
vivo
efficaci
model
exampl
substanti
improv
diseas
outcom
increas
surviv
reduc
sign
neuroinfect
viral
titer
brain
balbc
mice
infect
lethal
dose
compound
also
reduc
viremia
mice
infect
african
strain
moreov
protect
suckl
mice
challeng
hamster
infect
lethal
dose
yfv
even
administ
three
day
similar
nucleosid
analog
possess
modif
initi
identifi
promis
inhibitor
hcv
polymeras
sofosbuvir
phosphoramid
prodrug
develop
gilead
scienc
inc
one
potent
select
inhibitor
seri
approv
food
drug
administr
fda
treatment
chronic
hcv
sofosbuvir
nontox
human
cell
line
poor
substrat
human
mitochondri
rdrp
result
accept
safeti
profil
neglig
mitochondri
sofosbuvir
demonstr
inhibit
zikv
rdrp
recombin
polymeras
suppress
zikv
replic
differ
cellbas
system
use
glioblastoma
cell
babi
hamster
kidney
fibroblast
neuroblast
hepatocarcinoma
cell
jar
human
placent
choriocarcinoma
cell
neural
stem
cell
brain
organoid
nanomolar
low
micromolar
inhibitori
interestingli
inhibit
zikv
replic
sofosbuvir
even
level
observ
vero
indic
sofosbuvirmedi
antizikv
effect
strongli
celltyp
sofosbuvir
protect
inbr
mice
previous
immunosuppress
singl
dose
block
monoclon
antibodi
zikvinduc
moreov
compound
reduc
viral
titer
blood
plasma
spleen
kidney
brain
suckl
swiss
albino
mice
prevent
virusinduc
neuromotor
impair
zikvinfect
surprisingli
howev
sofosbuvir
inact
tbev
screen
ps
anoth
modifi
nucleosid
prodrug
mericitabin
also
display
activ
tbev
replic
lack
antitbev
activ
modifi
nucleosid
could
ascrib
ineffici
intracellular
convers
correspond
triphosph
moreov
extens
deaminationdemethyl
test
cell
cultur
result
convers
substitut
nucleosid
primarili
identifi
inhibitor
repres
lead
compound
seri
inhibit
replic
cellbas
assay
valu
deriv
denot
inhibit
denv
differ
serotyp
submicromolar
low
micromolar
concentr
test
cell
cell
hepatocarcinoma
cell
human
peripher
blood
mononuclear
cell
pbmc
show
significantli
improv
cytotox
profil
compar
also
assay
wnv
yfv
zikv
exhibit
excel
vitro
inhibitori
paramet
protect
effect
wnv
zikv
infect
mous
efficaci
also
report
effect
inhibit
vitro
replic
tbev
ahfv
kdfv
ohfv
powv
nanomolar
low
micromolar
antivir
level
observ
variou
cellbas
screen
introduct
carbamoyl
moieti
molecul
provid
anoth
modifi
deriv
refer
despit
low
micromolar
antidenv
efficaci
nucleosid
disappointingli
exhibit
low
level
plasma
dose
increas
oral
bioavail
isobutyryl
ester
prodrug
design
synthes
success
exhibit
nanomolar
antidenv
activ
well
improv
pharmacokinet
although
show
antidenv
potenc
rodent
model
even
treatment
delay
h
infect
nucleosid
fail
preclin
toxic
studi
rat
dog
due
insuffici
safeti
fail
achiev
noobservedadverseeffect
level
noael
rat
mgkgday
dog
mgkgday
dose
daili
two
similarli
noael
achiev
twoweek
toxic
test
rat
dose
substitut
posit
fluoro
cyano
moieti
provid
compound
nano
low
micromolar
antidenv
activ
accept
cytotox
profil
contrast
vinyl
methylethynyl
substitut
deriv
complet
inact
test
denv
similarli
exchang
adenin
base
cytosin
guanin
also
yield
inact
substitut
adenosin
guanosin
cytidin
uridin
evalu
potenti
antitbev
activ
howev
neglig
antivir
effect
observ
test
ps
abrog
nucleosid
inhibitori
activ
could
relat
elimin
hydrogen
bond
donoracceptor
properti
methyl
moieti
introduc
nucleosid
abil
flavivir
rdrp
discrimin
among
nucleosid
modifi
nucleosid
like
relat
need
polymeras
avoid
incorpor
monophosph
viral
nascent
rna
methyl
posit
gener
correspond
modifi
structur
result
complet
loss
antitbev
activ
regardless
purinepyrimidin
heterobas
ident
nucleosid
exert
cytotox
effect
caus
morpholog
chang
ps
porcin
embryo
kidney
pek
cell
similarli
exhibit
detect
inhibitori
effect
tbev
contrast
sever
nucleosid
trityl
group
posit
show
micromolar
inhibitori
activ
denv
yfv
see
observ
inact
nucleosid
could
relat
either
strict
requir
tbev
rdrp
activ
site
group
form
appropri
hydrogen
bond
interact
nucleosid
triphosph
molecul
ineffici
cellular
uptak
metabol
convert
nucleosid
molecul
correspond
triphosph
use
highthroughput
screen
larg
nucleosid
librari
combin
ration
drug
design
approach
investig
roch
sever
cytidin
analog
azido
group
posit
identifi
potent
inhibitor
hcv
replic
subgenom
replicon
later
shown
compound
also
highli
activ
henipavirus
two
modifi
nucleosid
analog
show
nano
micromolar
vitro
antivir
activ
moreov
compound
found
activ
also
wnv
l
eyer
manuscript
prepar
antitbev
activ
arabinocounterpart
unexpect
compound
lack
moieti
determin
gener
consid
crucial
specif
hydrogenbond
interact
rdrp
rna
replic
addit
interact
polymeras
activ
site
substitu
substitu
thought
compens
loss
interact
result
strong
select
antitbev
activ
interestingli
antitbev
efficaci
modifi
nucleosid
celltyp
depend
compound
activ
ps
cell
ester
prodrug
denot
balapiravir
complet
inact
tbev
vitro
probabl
poor
intracellular
uptak
insuffici
kinas
phosphoryl
test
host
cell
contrast
balapiravir
report
show
strong
vitro
antivir
activ
denv
variou
serotyp
first
direct
antivir
agent
test
clinic
denv
infect
unfortun
compound
fail
achiev
antivir
efficaci
denv
patient
reflect
neglig
reduct
denv
viremia
persist
clinic
symptom
even
though
plasma
concentr
compound
higher
effect
one
possibl
explan
denv
infect
stimul
pbmc
produc
cytokin
respons
decreas
effici
convers
balapiravir
triphosph
interestingli
nucleosid
analog
combin
moieti
group
one
molecul
eg
exhibit
antivir
activ
test
hcv
howev
correspond
prodrug
display
consider
improv
viru
inhibitori
effect
valu
micromolar
rang
without
appar
interest
compound
ester
prodrug
found
show
nano
low
micromolar
antivir
efficaci
unfortun
nucleosid
scaffold
evalu
arthropodborn
flavivirus
report
result
origin
hcv
repliconbas
develop
biocryst
pharmaceut
inc
adenosin
analog
furanos
oxygen
ribos
ring
replac
nitrogen
heterobas
nitrogen
replac
interest
nucleosid
classifi
initi
describ
inhibitor
filoviru
infect
exert
antivir
activ
broad
spectrum
singlestrand
rna
virus
particularli
member
bunyavirida
arenavirida
picornavirida
orthomyxovirida
paramyxovirida
coronavirida
flavivirida
current
compound
enter
phase
clinic
trial
ebola
viru
diseas
treatment
focus
intramuscular
administr
healthi
volunt
date
shown
promis
pharmacokinet
properti
good
activ
numer
mosquitotransmit
flavivirus
wnv
repres
african
asian
lineag
zikv
yfv
jev
micromolar
valu
vivo
efficaci
also
demonstr
lethal
hamster
model
yfv
infect
mous
model
zikv
low
micromolar
antivir
activ
also
describ
medic
import
tickborn
flavivirus
tbev
liv
heterocycl
basemodifi
nucleosid
demonstr
antiflavivir
activ
includ
numer
aryl
substitut
ribosyl
analog
pyrazin
deriv
favipiravir
describ
inhibit
hcv
rdrp
enzym
nucleosid
inhibitor
display
neglig
vitro
activ
yfv
vero
cell
well
luciferasebas
contrast
compound
exert
favor
efficaci
bioavail
low
toxic
hamster
model
yfv
infect
use
hamsteradapt
jimenez
yfv
strain
intraperiton
applic
mgkgday
improv
surviv
rate
serum
paramet
weight
gain
mean
day
death
administ
four
day
viru
model
combin
ribavirin
gave
superior
effect
compar
monotherapi
either
ribavirin
hydrophob
mimic
adenosin
show
nanomolar
antivir
activ
vero
cellbas
screen
system
well
luciferasedriven
replicon
assay
cytotox
effect
note
h
relat
compound
complet
inact
test
mechanist
studi
reveal
nucleotid
effici
substrat
viral
rdrp
screen
polio
rdrp
incorpor
nascent
viral
rna
strain
mimick
atp
aryl
substitut
nucleosid
origin
identifi
inhibitor
lassa
fever
viru
marburg
viru
enteroviru
show
interest
bioactiv
profil
test
wherea
complet
inact
nucleosid
bulki
substitu
adenosin
adenosin
exert
micromolar
antitbev
effect
contrast
analog
show
antivir
activ
moder
antiyfv
antidenv
activ
also
observ
analog
mechan
action
nucleosid
poorli
understood
howev
like
interact
rdrp
mtase
domain
flavivir
protein
demonstr
dock
bulki
aromat
substitu
could
also
play
role
interact
viral
membran
result
cell
entri
largescal
cellbas
screen
campaign
alkyl
silyl
acyl
pyrimidin
nucleosid
identifi
inhibitor
yfv
replic
show
high
antivir
potenc
favor
cytotox
profil
vero
substanti
antivir
effect
yfv
observ
also
sever
bistrityl
pyrimidin
nucleosid
howev
antidenv
activ
proven
thymidin
congen
nucleosid
led
loss
antiflaviviru
activ
increas
compound
cytotox
mechan
action
trityl
nucleosid
complet
understood
base
observ
inhibit
denv
replic
subgenom
replicon
assay
assum
compound
may
act
inhibitor
intracellular
viral
replic
event
rather
suppress
either
earli
late
process
viral
infect
entri
although
presenc
larg
hydrophob
trityl
moieti
make
structur
ideal
candid
drug
develop
chemic
structur
may
provid
valuabl
inform
advanc
mechanist
studi
develop
relat
nucleosid
scaffold
improv
biolog
domain
flavivir
protein
associ
viru
mtase
activ
involv
methyl
structur
genom
flavivir
cap
structur
form
conserv
dinucleotid
sequenc
ag
crucial
mrna
stabil
effici
two
topolog
distinct
methyl
reaction
mediat
flavivir
mtase
guanin
methyl
mtase
first
nucleotid
rna
transcript
methyl
ribos
mtase
result
product
methyl
donat
methyl
reaction
sadenosyllmethionin
nucleosid
analog
sadenosyllhomocystein
sah
sah
nucleosid
antibiot
sinefungin
natur
nonselect
inhibitor
mani
eukaryot
viral
mtase
includ
chemic
derivat
sah
posit
provid
inhibitor
nano
low
micromolar
activ
denv
mtase
inhibit
correspond
human
ration
design
nucleosid
potent
inhibitori
activ
mtase
contain
thymin
base
hydrophob
methyl
tertbutyl
substitu
posit
sugar
two
nucleosid
inhibit
mtase
activ
wnv
enzymebas
assay
observ
mtase
inhibit
agreement
micromolar
vitro
antiwnv
anoth
class
promis
select
antiflaviviru
compound
repres
nucleosid
scaffold
deriv
similar
structur
origin
develop
protect
group
bulki
triazol
substitu
appear
crucial
structur
element
low
micromolar
inhibit
flavivir
mtase
enzymebas
assay
well
inhibit
wnv
denv
replic
cell
cultur
nucleosid
inhibit
methyl
reaction
competit
interact
substrat
bind
site
also
gtpbind
pocket
flavivir
recent
novel
seri
flexibl
nucleosid
analog
known
flexim
exhibit
activ
sever
hard
treat
virus
includ
filovirus
ebola
coronavirus
includ
sever
acut
respiratori
viru
middl
east
respiratori
well
recent
flavivirus
includ
zikv
denv
flexim
featur
split
purin
nucleobas
shown
impart
signific
activ
nucleosid
scaffold
well
allow
overcom
resist
relat
point
recent
seri
combin
flexim
approach
acycl
nucleosid
acyclovir
fda
approv
drug
herp
viru
analog
inhibit
aforement
virus
acyclovir
show
activ
virus
therebi
underscor
import
flexim
approach
sinc
initi
find
compound
also
demonstr
potent
activ
denv
zikv
k
seleyradtk
manuscript
prepar
preliminari
result
indic
compound
target
denv
zikv
least
capmtas
activ
neglig
effect
cognat
human
regard
initi
screen
reveal
promis
level
mtase
inhibit
particularli
triphosph
compound
flex
denv
zikv
k
seleyradtk
manuscript
prepar
result
flex
test
denv
incorpor
success
inhibit
incorpor
addit
nucleotid
therebi
halt
replic
howev
typic
chain
termin
addit
acetateprotect
dimethoxi
analog
flex
potent
denv
inhibitor
unpublish
result
smee
laboratori
utah
howev
work
need
done
fulli
elucid
novel
compound
mechan
action
may
well
nucleotid
analog
target
protein
rdrp
mtase
region
would
make
highli
effect
viral
inhibitor
low
probabl
viral
resist
develop
flavivir
ntpase
helicas
activ
associ
coohproxim
domain
flavivir
helicas
capabl
unwind
duplex
rna
structur
viral
replic
disrupt
hydrogen
bond
keep
two
strand
helicas
activ
strictli
associ
ntp
hydrolysi
ntpase
activ
releas
chemic
energi
use
transloc
enzym
along
doublehelix
structur
captur
expos
singl
strand
region
direct
disrupt
hydrogen
bond
two
rna
specif
nucleosid
inhibitor
flavivir
ntpasehelicas
interact
dsrna
dna
result
weaken
stabil
doublehelix
structur
steric
hindranc
transloc
enzym
along
polynucleotid
chain
mechan
could
modul
efficaci
unwind
reaction
ntpase
activ
enzym
therefor
affect
viral
replic
weak
inhibitori
effect
flavivir
ntpasehelicas
describ
ribavirin
ester
purin
halogen
benzotriazolemodifi
compound
primarili
evalu
enzymebas
assay
put
antihcv
activ
howev
found
inhibit
also
ntpasehelicas
wnv
jev
ribavirin
nucleosid
analog
featur
triazol
ring
nucleobas
licens
drug
variou
rna
virus
predomin
inhibitori
mechan
ribavirin
flavivir
replic
suppress
de
novo
biosynthesi
guanin
nucleotid
direct
inhibit
inosin
monophosph
dehydrogenas
enzym
convert
inosin
monophosph
xanthosin
monophosph
precursor
gtp
specul
mode
action
ribavirin
includ
specif
inhibit
viral
accumul
mutat
viral
genom
result
error
interfer
mrna
cap
immunomodul
promot
antivir
ribavirin
shown
exert
moder
inhibitori
effect
multipl
mosquitoborn
flavivirus
variou
cell
often
use
posit
control
mani
vivo
antivir
ribavirin
administ
yvfinfect
hamster
challeng
intraperiton
result
signific
improv
surviv
rate
even
therapi
start
two
day
postyfv
contrast
howev
primat
weak
prophylact
effect
viremia
rhesu
monkey
challeng
denv
sever
ribavirin
deriv
recent
synthes
show
interest
bioactiv
profil
etar
triazol
imidazol
inhibit
replic
vero
cell
compar
ribavirin
show
detect
cytotox
effect
anoth
deriv
eicar
report
possess
similar
vitro
spectrum
antivir
activ
lower
select
compar
two
nucleosid
whose
antivir
activ
base
deplet
intracellular
nucleosid
pool
deriv
inhibitor
orotidin
monophosph
decarboxylas
block
cellular
de
novo
pyrimidin
prove
activ
numer
arthropodborn
howev
exhibit
slight
cytotox
inhibitori
effect
growth
host
triacet
prodrug
show
low
micromolar
activ
ahfv
wnv
low
toxic
anim
human
anoth
deriv
exert
moder
inhibitori
effect
similar
result
achiev
use
compound
exhibit
synergist
vitro
antiyfv
activ
combin
interferon
mechan
action
current
unknown
howev
conceiv
like
resembl
nucleosid
deriv
contain
bulki
aromat
substitu
perylen
pyren
moieti
attach
heterocycl
base
origin
synthes
fluoresc
nucleosid
later
structur
identifi
inhibitor
herp
simplex
viru
type
vesicular
stomat
viru
sindbi
viru
studi
demonstr
broadspectrum
antivir
activ
envelop
virus
influenza
viru
murin
cytomegaloviru
mechan
action
rigid
amphipath
nucleosid
base
incorpor
viral
cellular
membran
prevent
altern
nucleosid
may
also
function
photosensit
lipid
membran
result
irrevers
damag
envelop
virion
ethynylarabinouridin
shown
act
strong
inhibitor
tbev
pek
cell
perylen
moieti
well
rigid
ethynyl
linker
appear
crucial
structur
element
nanomolar
antitbev
activ
low
cytotox
interestingli
uracil
nucleosid
bear
pyren
moieti
show
almost
lower
antitbev
potenc
compar
perylenesubstitut
counterpart
compound
use
therapeut
agent
could
still
contribut
better
understand
differ
mode
action
variou
nucleosid
introduct
variou
chemic
substitu
differ
posit
nucleosid
scaffold
dramat
affect
physicochem
properti
compound
modif
also
significantli
influenc
compound
biologicalpharmacokinet
paramet
cellular
abil
compound
activ
phosphoryl
cellular
degrad
nucleosid
catabol
cellular
use
nucleosid
analog
also
result
undesir
emerg
drugresist
viru
section
highlight
import
challeng
complic
toward
develop
nucleosid
inhibitor
arthropodtransmit
flavivirus
suggest
possibl
strategi
surmount
difficulti
nucleosid
analog
first
kinas
phosphoryl
ratelimit
step
convers
nucleosid
triphosph
limit
major
influenc
nucleosid
analog
antivir
bypass
use
monophosph
prodrug
approach
base
introduct
phosphoryl
group
nucleosid
posit
phosphoryl
group
includ
mask
moieti
charg
phosphat
lead
neutral
eventu
hydrophob
entiti
abl
deliv
nucleosid
cell
figur
monophosph
prodrug
approach
shown
convert
inact
nucleosid
strong
inhibitor
improv
kinet
paramet
intracellular
nucleosid
triphosph
strategi
togeth
enantioselect
purif
led
develop
phosphoramid
prodrug
sofosbuvir
exhibit
consider
increas
phosphoryl
efficaci
compar
parent
nucleosid
rapid
degrad
nucleosid
analog
nucleosid
catabol
pathway
figur
anoth
undesir
phenomenon
advers
affect
antivir
potenc
nucleosid
address
problem
appropri
structur
chang
introduc
nucleosid
scaffold
protect
nucleosid
metabol
strategi
success
found
rapidli
deamin
cellular
adenosin
deaminas
inact
inosin
deriv
andor
degrad
purin
nucleosid
phosphorylas
result
poor
bioavail
rapid
clearanc
nucleosid
substitut
adenin
nitrogen
carbon
provid
metabol
stabl
poor
substrat
nucleosid
catabol
enzym
compound
character
excel
bioavail
halflif
beagl
dog
rhesu
anoth
possibl
strategi
increas
metabol
stabil
therapeut
nucleosid
base
introduct
cglycosid
bond
nucleosid
scaffold
gener
cnucleosid
analog
major
advantag
cnucleosid
canon
nnucleosid
lie
resist
unwant
phosphorolysi
intracellular
phosphorylas
otherwis
would
cleav
nglycosid
individu
host
cellular
type
display
differ
express
level
nucleosid
kinas
enzymesprotein
involv
nucleosid
metabol
transport
result
celltyp
depend
antivir
activ
manifest
differ
valu
inhibitor
assay
differ
cell
strong
antitbev
activ
ps
cell
associ
rapid
effici
nucleosid
convers
correspond
triphosph
hand
antitbev
effect
phosphoryl
product
observ
compound
test
similarli
loss
antizikv
activ
vero
cell
sofosbuvir
like
relat
increas
express
multidrug
resist
abc
transport
cell
line
result
efflux
compound
clearli
celltyp
depend
antivir
activ
nucleosid
consider
affect
result
antivir
screen
therefor
use
multipl
clinic
relev
cell
line
evalu
compound
antivir
activ
anoth
possibl
complic
nucleosid
drug
develop
undesir
toxic
profil
nucleosid
inhibitor
relat
poor
select
viral
human
typic
exampl
nonselect
nucleosid
analog
tubercidin
exhibit
high
vitro
cytotox
attribut
incorpor
tubercidin
monophosph
cellular
dnarna
human
contrast
two
deriv
tubercidin
select
recogn
flavivir
rdrp
nontox
mammalian
cell
nucleosid
analog
inhibit
mitochondri
dna
rna
polymeras
result
mitochondri
primari
reason
failur
sever
promis
nucleosidesprodrug
clinic
trial
shown
modifi
newli
develop
compound
also
evalu
genotox
mutagen
well
renal
cardiovascular
liver
toxic
use
variou
biochem
vitro
nevertheless
even
compound
success
pass
numer
vitro
test
still
exhibit
harm
side
effect
test
anim
observ
adenosin
analog
regard
avail
suitabl
anim
model
crucial
success
evalu
nucleosid
therapeut
vivo
antivir
efficaci
flavivirus
particularli
devn
zikv
readili
replic
caus
patholog
immunocompet
mice
therefor
use
rodent
anim
infect
model
substanti
overcom
problem
suckl
young
mice
lack
mice
lack
immunosuppress
use
appropri
model
evalu
nucleosid
vivo
howev
anim
defect
immun
respons
model
may
also
underestim
real
efficaci
test
compound
rodentadapt
flaviviru
strain
hamsteradapt
yfv
strain
miceadapt
denv
strain
zikv
african
strain
dakar
repres
possibl
option
vivo
antivir
studi
biolog
properti
virus
howev
consider
differ
compar
parent
humanadapt
anoth
issu
relat
length
therapeut
treatment
tick
mosquitoborn
flavivirus
caus
acut
infect
shorttim
treatment
durat
expect
rang
sever
day
contrast
chronic
diseas
hcv
hbv
hiv
infect
requir
longlast
sometim
lifelong
treatment
differ
acut
chronic
diseas
consid
preclin
develop
antiflavivir
inhibitor
thu
compound
show
insuffici
safeti
profil
test
treatment
chronic
infect
still
suitabl
safe
shortterm
therapi
acut
flavivir
antivir
therapi
base
chemic
inhibitor
viral
replic
accompani
rapid
emerg
drugresist
mutant
substanti
complic
cours
infect
treatment
seen
hiv
hbv
hcv
flavivirus
rapid
evolut
resist
nucleosid
inhibitor
observ
resist
associ
signatur
mutat
ahvf
tbev
zikv
within
activ
site
viral
rdrp
interestingli
biolog
properti
tbev
mutant
virus
dramat
affect
manifest
resistanceassoci
loss
viral
replic
efficaci
cell
cultur
highli
attenu
virul
phenotyp
mice
result
unusu
low
mortal
rate
mice
infect
mutant
tbev
mutant
resist
nucleosid
highli
sensit
substitut
combin
treatment
base
two
inhibitor
could
possibl
strategi
order
minim
risk
emerg
viral
drug
million
clinic
case
caus
arthropodborn
flavivirus
includ
numer
death
report
worldwid
annual
mani
case
infect
indic
import
pursuit
new
small
moleculebas
therapeut
combat
emerg
viral
pathogen
among
inhibitor
flavivirus
repres
critic
unmet
medic
need
regard
nucleosid
inhibitor
flavivir
rdrp
attract
target
antivir
drug
design
nucleosid
methyl
ethynyl
modif
posit
deriv
best
understood
antiflaviviru
nucleosid
analog
mani
initi
develop
treatment
hcv
infect
later
reemploy
suppress
replic
nonhcv
flavivirus
import
antiflaviviru
nucleosid
repres
inhibitor
nucleosid
biosynthesi
whose
mode
action
predominantli
base
deplet
intracellular
nucleosid
pool
nucleosid
inhibitor
flavivir
mtase
ntpasehelicas
well
newli
discov
flaviviru
inhibitor
trityl
nucleosid
rigid
amphipath
nucleosid
adenosin
deriv
whose
mechan
action
still
poorli
understood
use
initi
structur
start
point
develop
new
gener
nucleosid
scaffold
improv
biolog
paramet
taken
togeth
specif
nucleosid
analogbas
antivir
therapi
combin
effect
vaccin
strategi
could
provid
potent
prophylact
cur
tool
treat
human
infect
caus
flavivirus
